ZyVersa Therapeutics (NASDAQ:ZVSA) has announced a publication in Molecular Neurobiology that reinforces data showing that its Inflammasome ASC Inhibitor IC 100 can attenuate the inflammatory response causing neuronal damage in a multiple sclerosis model. The study demonstrated that NLRP3 inflammasomes play a significant role in the pathogenesis of multiple sclerosis, and that their inhibition can lead to significant decreases in neuronal damage and demyelination. ZyVersa is developing IC 100 to inhibit the formation of multiple types of inflammasomes and their associated ASC specks to attenuate damaging inflammation.